OFFICIAL PUBLICATION OF

by its subsidiary APPco

TGA issues inhaler alert

Nicholas O’Donoghue 31/01/2024

No recall for Boehringer Ingelheim’s Spiriva Respimat Solution for Inhalation 2.5μg, despite issues with the product's inhaler device Patients are being urged to continue using Boehringer Ingelheim’s Spiriva Respimat Solution for Inhalation 2.5μg, despite an alert from the Therapeutic Goods Administration (TGA) regarding the product’s inhaler device. The TGA said that the alert

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Why not fund that pharmacist to become a doctor?’

They already sold their souls to fatten their bank accounts decades ago. Every penny counts for them and ticking boxes…

L L

‘Why not fund that pharmacist to become a doctor?’

60DD doesn’t mean demand will drop. It just means the money will reduce. The need for us will still be…

John Smith

Queensland commences shift towards ‘fuller scope of practice’

It is scary that the QLD gov has caved in to the whims and desire of the PGA. What concerns…

Morbidly Obese John

Pharmacist who ‘could barely stand’ while working drunk appeals decision

Showing empathy and helping the person find the support they need to recover is the best approach. It is important…

(Mary) Kay Dunkley

TGA issues inhaler alert

Previous Silos, restrictions and inconsistency named as scope barriers

Next ‘Every time there is a disaster…’

Clinical tips: Timing!

Clinical tips: Movement disorders

Clinical tips: Worms, Worms, Worms

Intranasal Midazolam for at home use

MENU

Previous Silos, restrictions and inconsistency named as scope barriers

Next ‘Every time there is a disaster…’

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.